You are here

Evaluation of a 3-dose Vaccination Regimen With One of Three Ascending Dose Levels of Clostridium Difficile Vaccine With or Without Adjuvant in Healthy Adults Aged 50 to 85 Years

Last updated on May 9, 2018

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Pembroke Pines, Florida, 33026 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Clostridium Difficile Associated Disease
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
50-85 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Evidence of a personally signed and dated informed consent document.

2. Healthy male and female adults aged 50 to 85 years at enrollment as determined by
medical history, physical examination, and the clinical judgment of the investigator
to be eligible for the study. Subjects with preexisting chronic medical conditions
determined to be stable may be included.

3. Male subjects who, in the opinion of the investigator, are biologically capable of
fathering children, and who are sexually active with women of childbearing potential
must agree to use a highly effective method of contraception from the time of informed
consent through at least 28 days after the last dose of investigational product
(through Visit 9 at Month 7).

4. Female subjects who are not of childbearing potential (ie, meet at least one of the
following criteria):

- Have undergone hysterectomy or bilateral oophorectomy;

- Have medically confirmed ovarian failure or

- Are medically confirmed to be postmenopausal

5. Availability for the entire duration of the study, and able to comply with scheduled
visits, treatment plan, laboratory tests, and other study procedures including
completion of the electronic diary (eDiary) from Day 1 to Day 7 following each
vaccination.

6. Ability to be contacted by telephone during study participation.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

1. Previous administration of an investigational C. difficile vaccine or C. difficile
monoclonal antibody therapy.

2. Proven or suspected prior episode of CDAD.

3. Unstable chronic medical condition or disease requiring significant change in therapy
or hospitalization for worsening disease within 12 weeks before receipt of study
vaccine.

4. Serious chronic medical disorders including metastatic malignancy, severe chronic
obstructive pulmonary disease (COPD) , end stage renal disease with or without
dialysis, clinically unstable cardiac disease, or any other disorder that in the
investigator's opinion precludes the subject from participating in the study.

5. Donation of blood volume of 250 mL or greater, or donation of plasma within 3 months
prior to enrollment or during the conduct of the study.

6. Bleeding diathesis or condition associated with prolonged bleeding time that may
contraindicate intramuscular injection or blood draw including subjects taking
anticoagulant, antiplatelet and/or antithrombotic agents except for low dose daily
aspirin (?325mg per day) within 30 days before enrollment through completion of Visit
9 (Month 7).

7. Any contraindication to vaccination or vaccine components.

8. "Immunocompromised persons or subjects currently on immunosuppressive therapy or with
a history of immunosuppressive therapy, including chemotherapy agents for treatment of
diseases including, but not limited to cancer, inflammatory bowel disease or
autoimmune disease. Recent history (within the past 6 months) of long term (7 days or
longer) systemic corticosteroid use."

9. Subjects who received oral or parenteral antibiotics within 1 month before enrollment.
Topical antibiotics are allowed.

10. Receipt of blood products or immunoglobulins (including monoclonal antibodies) within
6 months before enrollment through conclusion of the study.

11. Participation in other investigational or interventional studies within 30 days before
the current study begins and/or during study participation. Participation in purely
observational studies is acceptable.

12. Subjects who are investigational site staff members or relatives of those site staff
members, or subjects who are Pfizer employees directly involved in the conduct of the
trial.

13. Females of childbearing potential; males of childbearing potential not using highly
effective contraception or not agreeing to continue highly effective contraception for
at least 28 days after last dose of investigational product (through Visit 9 at Month
7).

14. Females receiving exogenous estrogen therapy.

15. Residence in a nursing home, long-term care facility, requirement for semiskilled
nursing care or assisted living. An ambulatory subject who lives in an autonomous
manner in a retirement home or village is eligible for the trial.

16. Any abnormality in screening hematology and/or blood chemistry laboratory values
according to the toxicity grading scale. Subjects with stable Grade 1 abnormalities
for hemoglobin, leukocyte count, and platelets may be considered eligible at the
discretion of the investigator.

17. A positive screening test or known infection with human immunodeficiency virus (HIV),
hepatitis B virus (HBV) and/or hepatitis C virus (HCV).

18. Other severe acute or chronic medical or psychiatric condition or laboratory
abnormality that may increase the risk associated with study participation or
investigational product administration or may interfere with the interpretation of
study results and, in the judgment of the investigator, would make the subject
inappropriate for entry into this study.

NCT01706367
Pfizer
Completed
Evaluation of a 3-dose Vaccination Regimen With One of Three Ascending Dose Levels of Clostridium Difficile Vaccine With or Without Adjuvant in Healthy Adults Aged 50 to 85 Years

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Gastroesophageal Reflux Disease
NCT02401035
All Genders
1+
Years
Multiple Sites
Chronic Disease, Pain
NCT01179191
All Genders
21+
Years
Multiple Sites
Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
NCT03248882
All Genders
18+
Years
Multiple Sites
Evaluation of a 3-dose Vaccination Regimen With One of Three Ascending Dose Levels of Clostridium Difficile Vaccine With or Without Adjuvant in Healthy Adults Aged 50 to 85 Years
A Phase 1, Placebo-Controlled, Randomized, Observer-Blinded Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Clostridium Difficile Vaccine Administered With Or Without Adjuvant, In A 3-Dose Regimen In Healthy Adults Aged 50 To 85 Years
This is a first-in-human study (phase 1) of a 3-dose vaccination regimen with one of three dose levels of C difficile vaccine with or without adjuvant in healthy adults aged 50 to 85 years. The main goal of the study is to determine how safe and well-tolerated the vaccine is. In addition, the study aims to assess the immune response to the C difficile vaccine.
Not Provided
Interventional
Phase 1
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Investigator)
Primary Purpose: Basic Science
Clostridium Difficile Associated Disease
  • Biological: C. difficile vaccine
    0.5 mL IM injection
  • Biological: C. difficile vaccine +adjuvant
    0.5 mL IM injection
  • Experimental: Low dose C diff vaccine
    Intervention: Biological: C. difficile vaccine
  • Experimental: Low dose C diff vaccine + adjuvant
    Intervention: Biological: C. difficile vaccine +adjuvant
  • Experimental: Mid dose C diff vaccine
    Intervention: Biological: C. difficile vaccine
  • Experimental: Mid dose C diff vaccine + adjuvant
    Intervention: Biological: C. difficile vaccine +adjuvant
  • Experimental: High dose C diff vaccine
    Intervention: Biological: C. difficile vaccine
  • Experimental: High dose C diff vaccine + adjuvant
    Intervention: Biological: C. difficile vaccine +adjuvant
Sheldon E, Kitchin N, Peng Y, Eiden J, Gruber W, Johnson E, Jansen KU, Pride MW, Pedneault L. A phase 1, placebo-controlled, randomized study of the safety, tolerability, and immunogenicity of a Clostridium difficile vaccine administered with or without aluminum hydroxide in healthy adults. Vaccine. 2016 Apr 19;34(18):2082-91. doi: 10.1016/j.vaccine.2016.03.010. Epub 2016 Mar 15.


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
192
January 2014
January 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Evidence of a personally signed and dated informed consent document.
  2. Healthy male and female adults aged 50 to 85 years at enrollment as determined by medical history, physical examination, and the clinical judgment of the investigator to be eligible for the study. Subjects with preexisting chronic medical conditions determined to be stable may be included.
  3. Male subjects who, in the opinion of the investigator, are biologically capable of fathering children, and who are sexually active with women of childbearing potential must agree to use a highly effective method of contraception from the time of informed consent through at least 28 days after the last dose of investigational product (through Visit 9 at Month 7).
  4. Female subjects who are not of childbearing potential (ie, meet at least one of the following criteria):

    • Have undergone hysterectomy or bilateral oophorectomy;
    • Have medically confirmed ovarian failure or
    • Are medically confirmed to be postmenopausal
  5. Availability for the entire duration of the study, and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures including completion of the electronic diary (eDiary) from Day 1 to Day 7 following each vaccination.
  6. Ability to be contacted by telephone during study participation.

Exclusion Criteria:

  1. Previous administration of an investigational C. difficile vaccine or C. difficile monoclonal antibody therapy.
  2. Proven or suspected prior episode of CDAD.
  3. Unstable chronic medical condition or disease requiring significant change in therapy or hospitalization for worsening disease within 12 weeks before receipt of study vaccine.
  4. Serious chronic medical disorders including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) , end stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that in the investigator's opinion precludes the subject from participating in the study.
  5. Donation of blood volume of 250 mL or greater, or donation of plasma within 3 months prior to enrollment or during the conduct of the study.
  6. Bleeding diathesis or condition associated with prolonged bleeding time that may contraindicate intramuscular injection or blood draw including subjects taking anticoagulant, antiplatelet and/or antithrombotic agents except for low dose daily aspirin (?325mg per day) within 30 days before enrollment through completion of Visit 9 (Month 7).
  7. Any contraindication to vaccination or vaccine components.
  8. "Immunocompromised persons or subjects currently on immunosuppressive therapy or with a history of immunosuppressive therapy, including chemotherapy agents for treatment of diseases including, but not limited to cancer, inflammatory bowel disease or autoimmune disease. Recent history (within the past 6 months) of long term (7 days or longer) systemic corticosteroid use."
  9. Subjects who received oral or parenteral antibiotics within 1 month before enrollment. Topical antibiotics are allowed.
  10. Receipt of blood products or immunoglobulins (including monoclonal antibodies) within 6 months before enrollment through conclusion of the study.
  11. Participation in other investigational or interventional studies within 30 days before the current study begins and/or during study participation. Participation in purely observational studies is acceptable.
  12. Subjects who are investigational site staff members or relatives of those site staff members, or subjects who are Pfizer employees directly involved in the conduct of the trial.
  13. Females of childbearing potential; males of childbearing potential not using highly effective contraception or not agreeing to continue highly effective contraception for at least 28 days after last dose of investigational product (through Visit 9 at Month 7).
  14. Females receiving exogenous estrogen therapy.
  15. Residence in a nursing home, long-term care facility, requirement for semiskilled nursing care or assisted living. An ambulatory subject who lives in an autonomous manner in a retirement home or village is eligible for the trial.
  16. Any abnormality in screening hematology and/or blood chemistry laboratory values according to the toxicity grading scale. Subjects with stable Grade 1 abnormalities for hemoglobin, leukocyte count, and platelets may be considered eligible at the discretion of the investigator.
  17. A positive screening test or known infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) and/or hepatitis C virus (HCV).
  18. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
Sexes Eligible for Study: All
50 Years to 85 Years   (Adult, Senior)
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01706367
B5091001
Yes
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
March 2014

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now